PUBLISH YOUR EVENTS!
Boston Professional Events List
3-hrs Webinar-Deciding When to Submit a 510(k) for a Change to an Existing Device – FDA’s Final Guidance
Date
Link to Website
Organizer
Venue
Location
Ticket Price: $295 One Dial-in One Attendee | Corporate Live Recorded $395 One Dial In - Max 10 attendees |Group $995 Multiple locations upto 5 dial in | Recorded $345
A premarket notification (510(k)) is required when a legally marketed device subject to 510(k) requirements is about to be significantly changed or modified in design, components, method of manufacture, or intended use. Significant changes or modifications are those that could significantly affect the safety or effectiveness of the device, or major changes or modifications in the intended use of the device (21 CFR 807.81(a)(3)).
This presentation, will aid manufacturers of medical devices who intend to modify a 510(k)-cleared device or a preamendments device subject to 510(k) (i.e., “existing devices”) during the process of deciding whether the modification exceeds the regulatory threshold of 21 CFR 807.81(a)(3) for submission and clearance of a new 510(k).
Why should you attend
This presentation uses the latest FDA thinking and guidance documents to assist the manufacturers in enhancing the predictability, consistency, and transparency of the “when to submit” decision-making process by providing a least burdensome approach, and describing in greater detail the regulatory framework, policies, and practices underlying such a decision.
Case Study Examples will be provided for each session to further assist the attendees in understanding how to decide when to submit a 510(k) for a change to an existing device.
Who will Benefit
• Quality Managers
• Quality Engineers
• Regulatory Affairs
• Small business owners
• GxP
• Consultants
• Quality VPs
• IT VPs
• Lab Directors
• Scientists
• FDA investigators
• Other regulatory agency investigators
Speaker Details
Speaker Profile
Angela Bazigos.CEO of Touchstone Technologies Inc. She has 40 years of experience in the Life Sciences & Healthcare Industries. Experience combines Quality Assurance, Regulatory Compliance, Business Administration, Information Technology, Project Management, Clinical Lab Science, Microbiology, Food Safety, Turnarounds and Business Development. Past employers / clients include Roche, Novartis, Genentech & PriceWaterhouseCoopers. Positions include Chief Compliance Officer at Morf Media. Co-authored & prototyped 21 CFR 11 guidance with FDA. Co-authored Computerized Systems in Clinical Research w/ FDA. Patent on speeding up software compliance. Recently quoted in Wall Street Journal for using training to bring regulatory compliance to the Boardroom.